Skip to main navigation menu Skip to main content Skip to site footer

Recurrent hemoptysis as a complication of cystic fibrosis. Implications for treatment

Hemoptisis recurrente como complicación de la fibrosis quística. Implicaciones para el tratamiento




Section
Presentación de casos

How to Cite
Recurrent hemoptysis as a complication of cystic fibrosis. Implications for treatment.
rev. colomb. neumol. [Internet]. 2014 Mar. 30 [cited 2024 Dec. 4];26(1). Disponible en: https://doi.org/10.30789/rcneumologia.v26.n1.2014.57

Dimensions
PlumX
license

Ninguna publicación, nacional o extranjera, podrá reproducir ni traducir sus artículos ni sus resúmenes sin previa autorización escrita del editor; sin embargo  los usuarios pueden descargar la información contenida en ella, pero deben darle atribución o reconocimiento de propiedad intelectual, deben usarlo tal como está, sin derivación alguna.

Jennifer Villar Zapata, MD.
    Nelson Lobelo, MD.
      Catalina Vásquez Sagra, MD.
        Jenny Jurado Hernández, MD.
          Amador Ovalle, MD.

            Jennifer Villar Zapata, MD.,

            Pediatra, Hospital Universitario Infantil de San José. Fundación Universitaria de Ciencias de la Salud. Bogotá, Colombia.


            Nelson Lobelo, MD.,

            Radiólogo Intervencionista, Hospital Universitario
            Infantil de San José.


            Catalina Vásquez Sagra, MD.,

            Neumólogo Pediatra, Fundación Neumológica Colombiana. Hospital Universitario Infantil de San José. Bogotá, Colombia.


            Jenny Jurado Hernández, MD.,

            Neumólogo Pediatra, Fundación Neumológica Colombiana. Hospital Universitario Infantil de San José. Bogotá, Colombia.

            Amador Ovalle, MD.,

            Neumólogo Clínico. Grupo Multidisciplinario de Fibrosis Quística, Hospital Universitario Infantil de San José. Bogotá, Colombia


            Hemoptysis is a commonly reported complication in patients with cystic fibrosis. It affects about 9% of the population. It can be of scarce quantity or massive (4%-5% of patients); the latter is defined as bleeding greater than 240 mL during a 24-hour period. Its pathogenesis is not completely understood, but the most commonly related cause is persistent inflammation of the airway associated with neovascularization, with tortuosity and damage of bronchial arteries, whose pressure values are systemic.

            We describe the case of a young patient with confirmed cystic fibrosis in whom hemoptysis was successfully controlled with a stepwise treatment of the complication.


            Article visits 1059 | PDF visits 2832


            Downloads

            Download data is not yet available.
            1. Consenso de fibrosis quística. Arch Argent Pediatr. 1999;97:188-224.
            2. Prados C, Máiz L, Antelo C, Baranda F, Blázquez J, Borro JM, et al Cystic fibrosis: consensus on the treatment of pneumothorax and massive hemoptysis and on the indications for lung transplantation. Arch Bronconeumol. 2000;36(7):411-6.
            3. Flume PA. Pulmonary complications of cystic fibrosis. Respir Care. 2009;54(5):618-27.
            4. Flume PA, Yankaskas JR, Ebeling M, Hulsey T, Clark LL. Massive hemoptysis in cystic fibrosis. Chest. 2005;128:729-738.
            5. Charan NB, Baile EM, Pare PD. Bronchial vascular congestion and angiogenesis. Eur Respir J. 1997;10:1173-1180.
            6. McDonald DM. Angiogenesis and remodeling of airway vasculature in chronic inflammation Am J Respir Crit Care Med. 2001;164:S39-S45.
            7. Jewkes J, Kay PH, Paneth M, Citron KM. Pulmonary aspergilloma: analysis of prognosis in relation to haemoptysis and survey of treatment. Thorax. 1983;38:572-578.
            8. Parker CM, Nolan R, Lougheed MD. Catamenial hemoptysis and pneumothoraces in a patient with cystic fibrosis. Can Respir J. 2007;14:295-297.
            9. McDonald DM. Angiogenesis and remodeling of airway vasculature in chronic inflammation Am J Respir Crit Care Med. 2001;164:S39-S45.
            10. Emerson J, Rosenfeld M, McNamara S, et al. Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr Pulmonol. 2002;34:91-100.
            11. Barben JU, Ditchfield M, Carlin JB, Robertson CF, Robinson PJ,Olinsky A. Major haemoptysis in children with cystic fibrosis: a 20 year retrospective study. J Cyst Fibr. 2003;2:105-111.
            12. Popper J. The use of premarin IV in hemoptysis. Dis Chest. 1960;37:659-60.
            13. Schidlow DV, Taussig LM, Knowles MR. Cystic Fibrosis Foundation consensus conference report on pulmonary complications of cystic fibrosis. Pediatr Pulmonol. 1993;15:187-98.
            14. Flume PA, Mogayzel PJ Jr, Robinson KA, Rosenblatt RL, Quittell L, Marshall BC. Cystic fibrosis pulmonary guidelines: pulmonary complications: hemoptysis and pneumothorax. Clinical Practice Guidelines for Pulmonary Therapies Committee; Cystic Fibrosis Foundation Pulmonary Therapies Committee. Am J Respir Crit Care Med. 2010;182:298-306.
            15. Coss-Bu JA, Sachdeva RC, Bricker JT, Harrison GM, Jefferson LS. Hemoptysis: a 10-year retrospective study. Pediatrics. 1997;100:E7.
            16. Sidhu M, Wieseler K, Burdick TR, Shaw DW. Bronchial artery embolization for hemoptysis. Semin Intervent Radiol. 2008;25:310-8.
            17. Barben J, Robertson D, Olinsky A, Ditchfield M. Bronchial artery embolization for hemoptysis in young patients with cystic fibrosis. Radiology 2002; 224:124–130.
            18. Antonelli M, Midulla F, Tancredi G, Salvatori FM, Bonci E, Cimino G, Flaishman I. Bronchial artery embolization for the management of nonmassive hemoptysis in cystic fibrosis. Chest. 2002;121: 796-801.
            19. Hurt K, Simmonds NJ. Cystic Fibrosis: Management of Haemoptysis.
            20. Paediatr Respir Rev. 2012; 13; 200-205.
            21. Flume PA, Mogayzel Jr PJ, Robinson KA, et al. Cystic Fibrosis Pulmonary Guidelines: Pulmonary Complications: Hemoptysis and Pneumothorax. Am J Respir Crit Care Med 2010;182: 298–306.
            22. Rolla M, D’Andrilli A, Rendina EA, Diso D, Venuta F. Cystic fibrosis and the thoracic surgeon. Eur J Cardiothorac Surg. 2011;39:716-25 Cystic fibrosis and the thoracic surgeon. Rolla M, D’Andrilli A, Rendina EA, Diso D, Venuta F.Eur J Cardiothorac Surg 2011;39:716–25.
            23. Ryan G, Jahnke N, Remmington T. Inhaled antibiotics for pulmonary exacerbations in cystic fibrosis. Cochrane Database of Systematic Reviews 2012; 12: CD008319.
            Sistema OJS 3.4.0.7 - Metabiblioteca |